Fig. 3From: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsTime on study treatment (navoximod dose BID), reason for treatment discontinuation, and best response by RECIST/change in sum of longest diameters for individual patients. PD: Progressive diseaseBack to article page